Compare IDXX & CRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDXX | CRH |
|---|---|---|
| Founded | 1983 | 1936 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Building Materials |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.1B | 68.2B |
| IPO Year | 1996 | 2002 |
| Metric | IDXX | CRH |
|---|---|---|
| Price | $572.35 | $103.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 14 |
| Target Price | ★ $715.00 | $137.50 |
| AVG Volume (30 Days) | 428.3K | ★ 5.0M |
| Earning Date | 04-30-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 1.47% |
| EPS Growth | ★ 22.59 | 9.76 |
| EPS | ★ 13.08 | 5.51 |
| Revenue | $4,303,702,000.00 | ★ $37,447,000,000.00 |
| Revenue This Year | $10.88 | $7.14 |
| Revenue Next Year | $8.59 | $5.22 |
| P/E Ratio | $43.99 | ★ $19.25 |
| Revenue Growth | ★ 10.42 | 5.27 |
| 52 Week Low | $356.25 | $76.75 |
| 52 Week High | $769.98 | $131.55 |
| Indicator | IDXX | CRH |
|---|---|---|
| Relative Strength Index (RSI) | 35.42 | 38.68 |
| Support Level | $567.62 | $99.03 |
| Resistance Level | $657.26 | $114.18 |
| Average True Range (ATR) | 15.01 | 2.86 |
| MACD | -0.05 | 0.62 |
| Stochastic Oscillator | 22.33 | 41.86 |
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
CRH is a global manufacturer of a range of building products used in construction projects, operating via a vertically integrated business model. The past decade has seen CRH transform into a leading building materials business, with increasing exposure to upstream building activities such as aggregates and cement. CRH's geographic footprint is mostly across developed markets. North America is CRH's largest market and accounts for 75% of EBITDA. The company is the largest producer of aggregates and asphalt in the US.